Qui sommes-nous ?
L'ANSM en bref
Nos engagements
Nos missions
Notre périmètre
Notre organisation
Déontologie et transparence
Publications institutionnelles
Publications scientifiques
Rejoignez-nous !
Notre agenda
 
Actualités
Nos articles
Nos campagnes
 
Bulletin officiel des actes, décisions et avis
Décisions institutionnelles
Décisions liées aux médicaments
Décisions liées aux produits sanguins et autres produits biologiques
Décisions liées aux médicaments dérivés du plasma
Décisions liées aux dispositifs médicaux et dispositifs médicaux de diagnostic in vitro
Injonctions
Décisions de police sanitaire
Sanctions financières
Avis
 
Disponibilité des produits de santé
Médicaments
Dispositifs médicaux et dispositifs médicaux de diagnostic in vitro
Vaccins
 
Vos démarches
Industriel
Organismes notifiés
Professionnel de santé
Patient
Chercheur

Our scope of action

A+ A-
ANSM’s scope of action covers the different categories of medicines (proprietary, generic, biosimilar, herbal, homoeopathic medicines, etc.) available on the market for adults and the paediatric population.

In the development of a medicine, ANSM is involved from the clinical trial phase. It subsequently grants, on a national level, a marketing authorisation (MA) based on the assessment of the benefits and risks of the medicine, and continues to conduct surveillance of its safety of use. Finally, ANSM has control over the advertising for these health products aimed at the public and healthcare professionals.

In the pages below, you will find definitions and general information on the different types of medicines, apart from  vaccines, which are covered in their own separate section.
 

Pharmaceutical preparations

What are pharmaceutical preparations ?

Pharmaceutical preparations are medicines produced from pharmaceutical starting materials and/or pharmaceutical products. They are defined in article L. 5121-1 of the French Public Health Code.
 
Find out more about reporting hospital preparations
Preparations are prepared and dispensed in accordance with Good Practice set out in Article L. 5121-5 under a pharmacist’s responsibility. They may only be prepared in the absence of an appropriate or available pharmaceutical product, including due to the lack of actual marketing.
A preparation is only undertaken after the pharmacist has verified that it is compliant with the regulations in force.

ANSM ensures regulation and safety.

What does ANSM do to ensure the safety of preparations ?

ANSM ensures that the use of a hospital preparation is justified, and reviews :
  • Preparations which do not meet an identified therapeutic need, and could be replaced by pharmaceutical products already available in France within the framework of a marketing authorisation (MA), or an early or special access authorisation.

    In this case, ANSM may request in-house pharmacies to review the suitability of these hospital preparations.
  • Preparations meeting an identified therapeutic need, which are necessary and have no therapeutic equivalent.  ANSM proposes a harmonisation of preparation formulas in order to improve and standardise their preparation and control in accordance with optimal quality. A formula is drafted and then published in the French Pharmacopoeia. The pharmacist is then required to strictly adhere to the formula described.
  • ANSM identifies “potentially at-risk” preparations, and assesses the adverse reactions reported for pharmacovigilance as for all medicines.

    It reviews the use of these preparations in hospital – and if necessary community – settings, by conducting a survey on in-house pharmacies and community pharmacies.

    It then assesses their toxicity, by requesting expert opinions. It may then take appropriate health policy measures such as bans, restrictions.
  • ANSM conducts inspections on pharmaceutical sites and pharmaceutical sites within healthcare institutions.

    The preparations obtained during these inspections are analysed by its laboratories. Corrective actions are requested, where applicable.
  • ANSM is involved in monitoring regulations, and more specifically in respect of the Good Preparation Practice that its drafts.

    It manages updates of the Good Preparation Practice guidance document applicable to community pharmacies and in-house pharmacies published in 2007. 
What is not a preparation
Some operations or some products are not preparations :
  • Reconstitution of pharmaceutical products strictly consisting of a mere mixing operation, in particular: of a solution, a powder, a freeze-dried product, etc. with a solvent for parenteral use or not, as indicated in the summary of product characteristics of the relevant pharmaceutical product.
  • Unpacking pharmaceutical products for the purposes of dispensing them to help administer the medicines to patients, insofar as their composition and their dosage form are not modified.
  • Some products such as: pastes for electrodes, lubricants for endoscopes, which are medical devices.
Reporting of adverse reactions associated with the use of a pharmaceutical preparation
All adverse reactions (harmful and undesirable reaction) associated with the use of hospital preparations must be reported to the national pharmacovigilance system.
The common adverse reaction reporting rules for all medicines apply to hospital preparations.
A specific code is assigned by ANSM for each reported hospital preparation. This helps optimise the reporting of any adverse reactions, and particularly link an adverse reaction with the administration of a given hospital preparation.
Reports may be submitted by patients, healthcare professionals, or pharmaceutical companies.
The procedure and forms for reporting adverse reactions are specific for each party involved.

Contact

ANSM responses to queries relating to regulatory, scientific, and also IT matters (use of the PrHosper electronic reporting tool).
 
Find out more about pharmaceutical preparations
 
Find out more about reporting hospital preparations
 
Find out more about Good Preparation Practice guidance
 
Find out more about the Temporary Specialist Scientific Committee for “review of Good Preparation Practice”